Reading ‘Australia’s Pandemic Exceptionalism’ and this official response report is essential for anyone likely to have ...

Stories on the discovery of vital fluid-transport systems in the human body are among the winners of the 2024 AAAS Kavli Science Journalism Awards. Winning journalists also did immersive stories on ...

Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen individualized therapeutic cancer vaccine, TG4050 at SITC ... reflects the discontinuation ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

AstraZeneca said it is in China ‘for the long haul’ and outlined billions of pounds of investment in the US – but a new ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine ...

The diplomatic row that broke out last week over the supply of AstraZeneca’s vaccine to Europe appears to have cooled after the UK pharma agreed to supply an extra nine million doses.

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP). The drugmaker said ...